Amgen (AMGN) reported Q2 adjusted earnings late Tuesday of $6.29 per diluted share, up from $6.02 a year earlier.
Analysts polled by FactSet expected $5.62.
Revenue for the quarter ended June 30 was $10.05 billion, up from $9.18 billion a year earlier.
Analysts expected $9.43 billion.
For the full-year 2026, the company now expects adjusted EPS of $22.30 to $23.50 on revenue of $38.2 billion to $39.4 billion, compared with its prior guidance of adjusted EPS of $21.70 to $23.10 on revenue of $37.10 billion to $38.50 billion.
Analysts expect $22.36 and $37.74 billion, respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.